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INTRODUCTION AND OBJECTIVE: Neoadjuvant and adjuvant therapies for soft tissue sarcomas of the extremities are still 
controversial. The aim of this study was to analyze the results of a protocol of neoadjuvant chemoradiation therapy for extremity 
sarcomas. 
METHODS: A retrospective analysis was carried out in a consecutive series of 49 adult patients with advanced extremity soft 
tissue sarcomas that could not be resected with adequate margins during the primary resection. All patients were treated with a 
protocol of preoperative radiation therapy at a total dose of 30 Gy, concomitant with doxorubicin (60 mg/m2) chemotherapy. The 
main endpoints assessed were local recurrence-free survival, metastasis-free survival and overall survival. The median follow-up 
time was 32.1 months. 
RESULTS: The five-year local recurrence-free survival, metastasis-free survival and overall survival rates were 81.5%, 46.7% and 
58.3%, respectively. For high-grade tumors, the five-year metastasis-free and overall survival rates were only 36.3% and 41.2%, 
respectively. Severe wound complications were observed in 41.8% of the patients who underwent surgery. These complications 
precluded adjuvant chemotherapy in 73.7% (14/19) of the patients eligible to receive it. 
CONCLUSIONS: In this study, neoadjuvant chemoradiation therapy was associated with a good local control rate, but the distant 
relapse-free rate and overall survival rate were still poor. The high rate of wound complications modified the planning of adjuvant 
treatment in most patients.
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INTRODUCTION
Soft tissue sarcomas (STS) are rare neoplasms. These 
tumors can originate in any tissue of mesenchymal 
origin and are localized to the limbs in approximately 
50% of cases. Historically, the proximity of the lesions 
to neurovascular structures resulted in a high rate of 
amputations in order to excise adequate margins. Despite 
the radical treatment, however, most patients died due to 
recurrence in distant organs, particularly in the lungs. Since 
the 1980s, results published by institutions that performed 
conservative surgeries associated to adjuvant radiotherapy 
showed good rates of local control, from 78% to 91%, but 
they did not observe changes in overall survival rates.1-4 
While the combination of conservative surgery and adjuvant 
radiotherapy has shown a good rate of local control, from 
78% to 91%, this combination has not resulted in a change 
in the overall survival rate.5
The timing of the radiotherapy (i.e., pre- or postoperative) 
is still controversial. Preoperative radiotherapy has 
the advantage of lowering the rate of operative wound 
complications. Several additional advantages of preoperative 
radiotherapy have been described: 1) better tissue oxygenation 
occurs without previous surgical manipulation, which may 
increase the cytotoxic effect of radiotherapy; 2) smaller and 
less normal tissue included when planning is preoperative; and 
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3) as the tumor volume decreases, preoperative radiotherapy 
makes surgery technically more feasible in patients in whom 
it would be otherwise not possible to obtain an adequate three-
dimensional margin.6-8 The disadvantages of neoadjuvant 
radiotherapy are primarily related to the high rate of 
wound complications.9,10 Studies that tested the ability of 
concomitant chemotherapy to radiosensitize patients 
receiving preoperative radiotherapy have demonstrated 
that the treatment resulted in local control rates above 
90%.9,11 The objective of the present study was to determine 
the effects of neoadjuvant chemoradiation therapy in the 
treatment of extremity STS in adult patients from a single 
Brazilian institution. The main endpoints of the study were 
the five-year local relapse–free survival rate, metastasis-free 
survival rate and overall survival rate, and the secondary 
endpoints were the rates of operative wound complications 
and amputation.
PATIENTS AND METHODS
This study is a retrospective study of 49 consecutive 
adult patients with a high-risk primary STS of the 
extremities who were treated between January 1995 and 
December 2004. The study excluded patients with recurrent 
tumors that were previously treated with radiation or 
chemotherapy.
In accordance with the institutional protocol standardized 
in 1995, candidates for neoadjuvant chemoradiation therapy 
were chosen from adult extremity STS patients whose 
tumors could not be removed by primary resection with 
adequate tridimensional margins (1.5 to 2.0 cm) based 
on the positional relationship with bone or neurovascular 
structures. Candidates who met these criteria were included 
even if they had low-grade tumors. This judgment was made 
by the surgeon, based on the pretreatment physical exam and 
imaging data (CT or MRI).
Our institutional neoadjuvant protocol is based on 
the study of Eilber and colleagues from the University of 
California, Los Angeles.7,8 A total preoperative radiotherapy 
dose of 3000 cGy was used, with 250 cGy daily dose 
fractions five times a week (12 sessions). For concomitant 
chemotherapy, 20 mg/m2 doxorubicin was used on days 1, 
8 and 15, for a total dose of 60 mg/m2. Surgery was done 
four to six weeks after finishing radiotherapy. Patients 
who were less than 50 years old with high-grade tumors 
were candidates to receive adjuvant doxorubicin- and 
ifosphamide-based chemotherapy. The main endpoints of 
this study were the five-year local relapse-free survival 
rate, the metastasis-free rate and the overall survival rate. 
The secondary endpoints were the rate of operative wound 
complications and the amputation rate.
The study was approved by the Institutional Research 
Ethics Committee of the A.C. Camargo Cancer Hospital.
Of the 44 patients without metastasis at presentation, 
a univariate analysis was performed to identify variables 
associated with the risk of distant relapse and death. The 
variables analyzed were age, gender, presentation of disease 
(recurrent versus non-recurrent), tumor size (less than or 
greater than 10 cm), grade (low versus high grade) and 
wound-related postoperative complications. Any variables 
identified by the univariate analysis would then be used in a 
multivariate model.
The survival rates were determined using Kaplan-Meier 
curves. Survival curves were compared using the log rank 
test. The risks of distant relapse and death were estimated 
using a hazard ratio (HR) analysis. The median follow-up 
time was 31.3 months, and the rate of loss to follow-up was 
8.2%.
RESULTS
Table 1 shows the clinical characteristics of the patients 
included in this study.
Table 1 - Clinical characteristics of the patients
Variable n (%)
Age (median) 47 (16 – 72)
Gender Male 21 (42.9)
Female 28 (57.1)
Location Inferior extremity 35 (71.4)
Superior extremity 8 (16.3)
Groin and gluteal 
regions
4 (8.2)
Shoulder 2 (4.1)
Median size (cm) 15 (5 – 40)
Histologic subtype synovial sarcoma 11 (22.4)
liposarcoma 9 (18.4)
MFH / pleomorphic 9 (18.4)
leiomyosarcoma 5 (10.2)
unclassified 5 (10.2)
Others 10 (20.4)
Grade I 10 (20.4)
II 9 (18.4)
III 29 (59.2)
not classified 1 (2.0)
Stage I 9 (18.4)
II 5 (10.2)
III 30 (61.2)
IVb 5 (10.2)
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During preoperative treatment, 3 cases of grade 3 toxicity 
were observed, all of which were of a hematologic nature. 
No deaths related to the treatment occurred. In 16 cases 
(32.7%), a clinical response to the neoadjuvant treatment, 
described as a reduction of tumor size upon physical 
examination, was observed.
Of the 49 patients who completed neoadjuvant treatment, 
6 did not receive surgery: 3 refused surgery, 2 had systemic 
disease progression, and 1 had local progression. The rate 
of amputation among the 49 patients, as regards intention to 
treatment, was 14.3% (7 cases).
Of the 44 patients treated with curative intent (non-
metastatic at diagnosis), 6 patients developed local 
recurrence, 20 patients presented with a distant relapse, 
and 17 patients died after the median follow-up time 
of 31.3 months. The median time between surgery and 
distant recurrence was 13.2 months (range: 1.4 to 60.1). 
The local relapse-free rate, metastasis-free rate and overall 
survival rate at five years were 81.5%, 46.7% and 58.3%, 
respectively.
The univariate analysis for the risk of distant relapse is 
shown in Table 2. Histological grade was the only variable 
associated with the risk of a distant recurrence (OR=7.33; 
95% CI: 1.33 to 40.28; p=0.02). For the patients with high-
grade tumors (grades II and III), the five-year metastasis-
free rate and overall survival rate were 36.3% and 41.2%, 
respectively. In this population of patients, none of the 
variables analyzed were associated with the risk of death. As 
Table 2 - Univariate analysis of the risk of distant recurrence 
between 44 patients without metastasis at presentation
Variable HR (95% CI) p
Male 1.15 (0.61 – 2.16) 0.75
Age < 50 0.95 (0.51 – 1.79) 0.57
Recurrent at presentation 0.54 (0.14 – 2.07) 0.50
Tumor size < 10 cm 0.42 (0.03 – 5.31) 0.59
High grade 7.33 (1.33 – 40.20) 0.02
Wound complication 1.35 (0.38 – 4.62) 0.75
Figure 1 - Kaplan-Meier survival curves: A- local recurrence free–survival; B- distant recurrence free–survival; C- overall survival; D- distant relapse–free 
survival for low- and high-grade tumors
1062
CLINICS 2009;64(11):1059-64Neoadjuvant chemoradiation for extremity sarcomas
Aguiar Junior S et al.
only one variable was significantly associated with distant 
recurrence, we did not perform a multivariate analysis.
Of the 43 patients who received surgery, 18 (41.8%) 
had severe complications related to the operative wound. A 
severe complication in the operative wound was defined as 
the necessity for debridement of devitalized tissues. Most 
complications were associated with long periods of treatment 
until resolution.
Nineteen patients with high-grade non-metastatic tumors 
at admission who were less than 50 years of age were 
eligible to receive adjuvant chemotherapy in accordance with 
the institutional protocol. Of these, only 5 patients received 
postoperative chemotherapy. The other 14 (73.7%) did not 
receive chemotherapy due to complications related to the 
operative wound. The five-year metastasis-free survival rate 
was 49.9% for the group that did not receive chemotherapy 
and 33.3% for the 5 patients who received chemotherapy. 
This difference was not statistically significant (p=0.97).
DISCUSSION
Our results show a good local control rate that is 
comparable to the rates reported by other institutions. The 
amputation rate of 14.7% was above what was expected, but 
one must consider that the study is an analysis of a subgroup 
of patients with deep tumors having a median size of 15 cm, 
most of whom were pretreatment candidates for amputation. 
We observed a high rate of distant relapse and death, as 
demonstrated by the five-year metastasis-free survival rate 
and overall survival rate of 46.7% and 58.3%, respectively. 
Similar rates have also been observed in many specialized 
cancer treatment centers and reflect the current dilemma 
in the treatment of STS in adults. Despite advances in 
the local control of the disease and the increase in limb-
sparing surgeries, no significant improvements in the 
overall survival have occurred in recent decades, and 
the pulmonary relapse rate and death rate have remained 
practically unchanged.
A reduction in the distant metastasis rate, particularly for 
pulmonary metastasis, and an increase in the survival rate 
would be achievable using systemic adjuvant treatment.. 
Until now, treatment with the three drugs doxorubicin, 
dacarbazine and ifosphamide has resulted in a response rate 
greater than 20% in metastatic disease.5 For local disease, 
the use of adjuvant chemotherapy in STS has been analyzed 
both in prospective randomized trials and in meta-analyses 
or systematic reviews and remains very controversial.- 
Despite the controversies, if there is a benefit from 
systemic adjuvant chemotherapy, the treatment should be 
administered as early as possible. The high rate of surgical 
complications, which have been attributed to a preoperative 
radiotherapeutic effect, is frequently a limiting factor in the 
initiation of postoperative systemic treatment.
In our study, we observed a 41.8% rate of complications 
in the operative wound. This rate is similar to that the 
rate observed in a Canadian randomized controlled trial 
that compared pre- and postoperative radiotherapy in the 
treatment of sarcomas of the extremities: complications 
in the operative wound occurred in 35% of the patients 
treated before surgery and in 17% of patients who received 
postoperative radiotherapy.10
The complications that we observed presented as 
extensive dehiscences associated with remnant necrosis 
and required the debridement of devitalized tissues. The 
consequences of these complications resulted in a significant 
modification of the therapeutic plan in 14 of 19 patients 
(74%) who would have received adjuvant chemotherapy 
in our protocol but were unable to do so because of these 
complications.
Some studies have reported an improvement in the 
rate of complications in the operative wound by using 
more complex reconstruction techniques, such as the use 
of microsurgical flaps., In our institutional experience, 
the joint work of the surgical oncology team with the 
reconstructive surgery team in complex cases has resulted 
in good outcomes. The higher complexity and potential 
morbidity associated with microsurgical reconstruction is 
worth mentioning, and we do not believe that this strategy 
is a systematic solution for solving the problem of operative 
wound complications in all cases of extremity sarcomas, but 
it should be considered in select cases. 
Several protocols have used chemotherapy concomitantly 
with neoadjuvant radiotherapy. Many use doxorubicin 
concomitantly with radiotherapy in order to increase 
radiosensitivity. Non-systematic reviews have demonstrated 
a higher local control rate using preoperative radiotherapy 
and chemotherapy (radiochemotherapy) than adjuvant 
radiotherapy alone. While the better control has been 
attributed to the concomitant use of preoperative 
radiochemotherapy, it is also associated with a higher rate 
of postoperative complications, which ranged from 26% to 
30%.9,11,12 
A multi-institution Phase II clinical trial (RTOG 9514) 
tested a combination of adriamycin, ifosphamide and 
dacarbazine in three preoperative cycles concomitant with 
short course radiotherapy followed by surgery. The estimated 
three-year disease-free survival rate, metastasis-free survival 
rate and global survival rate were 56.6%, 64.5% and 75.1%, 
respectively. Sixty-one patients had surgery, 5 of whom 
underwent amputation (7.8%), and the researchers observed 
fatal toxicity in 5% of the patients and grade 4 toxicity in 
84%. 
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Some authors have questioned the necessity of 
neoadjuvant radiotherapy. The role of radiotherapy is 
local control, but it does not influence the control of 
micrometastatic disease. Chemotherapy has both a local and 
systemic effect. If the response rate with the exclusive use 
of neoadjuvant chemotherapy were significant, we could 
suppress radiotherapy in the initial phase of treatment, 
thereby minimizing the complications without excluding 
the possibility of using adjuvant radiotherapy. This approach 
would have the advantage of allowing the use of combined 
chemotherapy regimens at doses that are poorly tolerated 
when used in combination with radiotherapy, in order to 
reduce the risk of pulmonary relapses since the initial phase 
of the therapeutic plan. In this context, a multi-center phase 
II randomized trial has already tested systemic neoadjuvant 
chemotherapy using three cycles of a combination of 
adriamycin followed by a 24-hour continuous infusion of 
ifosphamide and compared the outcome to surgery alone in 
patients with non-metastatic high risk extremity, head and 
neck, trunk or pelvis sarcomas. Severe hematologic toxicity 
occurred in 8% of cases, resulting in one death. An objective 
physical and radiological response was observed in 29% of 
cases, being complete in 8%.
CONCLUSIONS
In our study, neoadjuvant chemoradiation therapy was 
associated with a good local control rate (81.5% at five 
years), but the distant relapse-free rate and overall survival 
rate were still poor (46.7% and 58.3%, respectively). 
Our results are far from excellent, due to the high rate of 
complications in the operative wound (41.8%) and the 
occurrence of distant relapses. Recently, we began a Phase 
II clinical trial to test the effectiveness of preoperative 
neoadjuvant chemotherapy (doxorubicin and ifosphamide) 
without radiotherapy. If we obtain a good response rate 
and see improvements in the rate of operative wound 
complications without an increase in the amputation rate, 
we will be able to evaluate preoperative chemotherapy in a 
multi-center Phase III study.
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